PR PolyResearch

Join Free

NASDAQ

PolyPid Ltd. - Ordinary Shares (PYPD)

♥ 597 Thanks from members

PolyPid Ltd. (PYPD) displays a strong bullish setup driven by FDA Priority Review for D-PLEX100 with a November 28, 2026 PDUFA date and a lucrative Azurity commercialization partnership, though tempered by ongoing operating losses and cash runway constraints.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Other Nasdaq Tickers

GraniteShares 2x Long AAPL Daily ETF (AAPB)

Apple Inc. (AAPL)

Direxion Daily AAPL Bear 1X ETF (AAPD)

Ascentage Pharma Group International - American Depository Shares (AAPG)

Direxion Daily AAPL Bull 2X ETF (AAPU)

Rocket Pharmaceuticals, Inc. - Warrant (RCKTW)